CCRA Investigational Product Management 2

Question 1

Good Manufacturing Practice (GMP) requirements for investigational products are primarily intended to ensure:

Accepted Answer

Product quality, identity, purity, and potency for subject safety and reliable trial results

Answer

Cost-effective production of clinical supplies

Answer

Rapid manufacturing to meet enrollment timelines

Answer

Compatibility with commercial packaging standards

Question 2

What information must appear on investigational product labels per GCP and regulatory requirements?

Accepted Answer

Trial number, protocol ID, subject/dose information, storage conditions, sponsor contact, and the statement 'For Clinical Trial Use Only'

Answer

Only the product name and lot number

Answer

Commercial product name and manufacturer address

Answer

Subject name, date of birth, and insurance information

Question 3

Subject medication compliance (adherence) is most commonly assessed in clinical trials by:

Accepted Answer

Pill/device counts, subject diaries, or plasma drug level measurements

Answer

Sponsor review of financial payment records

Answer

Investigator opinion during clinic visits

Answer

Subject self-report at final visit only

Question 4

If a site's pharmacy refrigerator storing investigational product fails overnight, the CRA should advise the site to:

Accepted Answer

Document the excursion details (temperature range, duration) and contact the sponsor's clinical supply team for disposition guidance before dispensing affected product

Answer

Immediately discard all affected IP without notifying the sponsor

Answer

Continue dispensing the product since one night is unlikely to matter

Answer

Replace the IP from their own supply

Question 5

An IP 'expiry date extension' means:

Accepted Answer

The sponsor has performed additional stability testing and obtained regulatory approval to extend the product's use-by date

Answer

The protocol enrollment period has been extended

Answer

The site can continue using expired IP if no new supplies are available

Answer

The IRB has approved additional drug use beyond the original period

Question 6

What is the purpose of a 'double-blind dummy' (matching placebo or active control) in a clinical trial?

Accepted Answer

To maintain blinding by ensuring all treatment arms have identical appearance, so neither subjects nor site staff can distinguish active from placebo

Answer

To reduce manufacturing costs

Answer

To provide a backup supply of investigational product

Answer

To satisfy FDA labeling requirements